ACP-105 Solution 10mg/ml – 50ml
| Application | Selective Androgen Receptor Modulator (SARM) |
| Concentration | 1% (10mg/ml) |
| Composition | 99% PEG400, 1% ACP-105 (>99% purity) |
| CAS | 899821-23-9 |
| Molar Mass | 329.21 g/mol |
| Chemical Formula | C16H19ClFNO |
| Synonyms | ACP-105 |
| Storage | Minimize open air exposure, store in a cool dry place |
| Terms | For laboratory research use only. Not for human or animal consumption. |
What Is ACP-105?
ACP-105 is a non-steroidal selective androgen receptor modulator (SARM) developed by Acadia Pharmaceuticals. It is characterized as a partial agonist at the androgen receptor with potent anabolic activity in muscle and bone alongside a favorable tissue selectivity profile in reproductive tissues. ACP-105 has been specifically investigated as a potential treatment for conditions involving both anabolic insufficiency and CNS dysfunction — its androgenic activity in hippocampal neurons has been studied in the context of radiation-induced cognitive decline, making it one of only a handful of SARMs with direct neuroprotection research data.
In rodent studies, ACP-105 demonstrated significant increases in lean body mass and grip strength at doses well below those that produced androgenic effects in prostate tissue. It also showed neuroprotective effects against radiation-induced cognitive impairment, positioning it as an important research tool at the intersection of anabolic pharmacology and CNS protection.
Mechanism of Action
ACP-105 binds the androgen receptor with high affinity, acting as a partial agonist that produces tissue-selective activation. The resulting anabolic gene programs in skeletal muscle and bone are activated with substantially greater selectivity over reproductive androgenic pathways than testosterone. In the brain, AR activation in hippocampal neurons has been shown to support cognitive function in models of injury or hormone deficiency.
Research Applications
- Muscle and bone anabolism: Lean mass and bone density endpoints in rodent models with favorable selectivity.
- Radiation-induced cognitive decline: Demonstrated neuroprotection against hippocampal damage in irradiated rodent models.
- Comparative SARM pharmacology: Intermediate potency useful in multi-arm SARM studies.
- CNS androgen receptor research: Hippocampal AR activation for cognitive and neuroprotection studies.
Related Research Compounds
ACP-105 joins AC262,536 as one of two SARMs with published CNS/cognitive data, making them natural comparative tools. Both are compared against established SARMs like Ostarine, Andarine (S4), and RAD-140 in comprehensive AR pharmacology studies.
For laboratory research use only. Not for human or animal consumption.
Reviews
There are no reviews yet.